Aspergillus antigen in serum, urine and bronchoalveolar lavage specimens of neutropenic patients in relation to clinical outcome.
about
Galactomannan detection for invasive aspergillosis in immunocompromized patientsDetection of urinary excreted fungal galactomannan-like antigens for diagnosis of invasive aspergillosisDetection of galactomannan in bronchoalveolar lavage of the intensive care unit patients at risk for invasive aspergillosisDiscordant rise in galactomannan antigenemia in a patient with resolving Aspergillosis, renal failure, and ongoing hemodialysisBronchoalveolar lavage galactomannan in diagnosis of invasive pulmonary aspergillosis among solid-organ transplant recipients.Semiquantitative detection by real-time PCR of Aspergillus fumigatus in bronchoalveolar lavage fluids and tissue biopsy specimens from patients with invasive aspergillosis.Urine as a specimen to diagnose infections in twenty-first century: focus on analytical accuracy.Utility of Aspergillus antigen detection in specimens other than serum specimens.Management of invasive pulmonary aspergillosis in non-neutropenic critically ill patientsAspergillus Polymerase Chain Reaction: Systematic Review of Evidence for Clinical Use in Comparison With Antigen Testing.Use of bronchoalveolar lavage to detect galactomannan for diagnosis of pulmonary aspergillosis among nonimmunocompromised hosts.Antigen detection, serology, and molecular diagnosis of invasive mycoses in the immunocompromised host.Invasive pulmonary aspergillosis in patients with COPD: a report of five cases and systematic review of the literature.Evaluation of human body fluids for the diagnosis of fungal infectionsRapid differentiation of Aspergillus species from other medically important opportunistic molds and yeasts by PCR-enzyme immunoassay.Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria.Laboratory diagnosis of invasive aspergillosis: from diagnosis to prediction of outcomeCurrent status and future perspectives on molecular and serological methods in diagnostic mycology.Aspergillus galactomannan enzyme immunoassay and quantitative PCR for diagnosis of invasive aspergillosis with bronchoalveolar lavage fluid.Bronchoalveolar lavage in immunocompromised patients with haematological malignancy--value of new microbiological methods.The use of biomarkers and molecular methods for the earlier diagnosis of invasive aspergillosis in immunocompromised patients.Serum and urine galactomannan testing for screening in patients with hematological malignancies.False-positive serum and bronchoalveolar lavage Aspergillus galactomannan assays caused by different antibiotics.Bronchoalveolar lavage galactomannan for the diagnosis of chronic pulmonary aspergillosis.Strong correlation between serum aspergillus galactomannan index and outcome of aspergillosis in patients with hematological cancer: clinical and research implications.Galactomannan detection in computerized tomography-based broncho-alveolar lavage fluid and serum in haematological patients at risk for invasive pulmonary aspergillosis.Clinical and Pathological Correlation in Pediatric Invasive Pulmonary Aspergillosis.Galactomannan, a Surrogate Marker for Outcome in Invasive Aspergillosis: Finally Coming of Age.
P2860
Q24240734-10971C68-8C44-496C-92B3-B97B06C7317BQ28482168-ACC26990-34F1-47D7-998C-79149BDFDA29Q33851382-224B5A3B-AFA2-4B78-9D3C-69DC5B3118ECQ33884936-786CE392-CE91-48E4-9A2C-26FF847C0AB2Q35913870-FA8A00FF-D077-4E8C-8E59-7DD4968D0704Q35922683-40D9E1FC-4E15-4AC4-AEAB-6D3FD5C8EB21Q35928243-1FD82D0C-E7C4-436F-BE55-A03DD9144A74Q35951605-9F3C4AC3-4CBB-42AF-B5EC-C2A61D92C058Q36087577-3AB0235B-2992-4B03-81D7-B47ED8E9EC2BQ36094242-0A0EEDA4-93FB-426E-A262-995C8DD30E90Q36098515-D9633DCB-0FF5-4351-B2B4-1F9C7EDD5132Q36567799-3A692E27-5D15-4BA8-B28A-D71B12279A17Q37095685-ECA33DF5-28EF-41D4-95F7-120DF9A2E8FFQ37104973-B1F7EA2C-C736-40A8-80B4-37A37396034CQ37157934-02164C4B-E2A7-41B6-83C7-8F9BAF94909FQ37164085-A044BD51-0E97-46C8-825F-E9D0601CA74EQ37287794-EE30F7DC-41F9-4079-8884-0831AF9D1D65Q37628677-317C9094-5270-4F71-A771-D1BCA53A2AD9Q37702655-B9150229-B283-464A-AA5F-A45CEA2910EBQ37865558-C2303141-4F5A-453F-B253-50D20CA0B2C4Q38508539-433124AA-F0FB-434A-95C2-963B97E52B2DQ38979166-71B9F66C-59B4-402F-A07D-BB8005E7A16DQ43146182-DEF56922-77E0-43A1-9BAB-B46298059EB1Q45031004-684E0F26-DCFE-407A-BEAF-2D99D6862523Q45242201-73EBCB2A-9092-4AC9-850A-2F22783130D6Q53653935-760CA0A6-8C0C-49D3-9A0B-3A27497C9A1EQ54260166-75806F1E-F315-4EA0-90C9-9E5070C74153Q55241833-DB5E7D9B-C4AE-465B-A240-F5E2C372618E
P2860
Aspergillus antigen in serum, urine and bronchoalveolar lavage specimens of neutropenic patients in relation to clinical outcome.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
2000年學術文章
@zh-hant
name
Aspergillus antigen in serum, ...... relation to clinical outcome.
@en
Aspergillus antigen in serum, ...... relation to clinical outcome.
@nl
type
label
Aspergillus antigen in serum, ...... relation to clinical outcome.
@en
Aspergillus antigen in serum, ...... relation to clinical outcome.
@nl
prefLabel
Aspergillus antigen in serum, ...... relation to clinical outcome.
@en
Aspergillus antigen in serum, ...... relation to clinical outcome.
@nl
P2093
P356
P1476
Aspergillus antigen in serum, ...... relation to clinical outcome.
@en
P2093
Lehtonen OP
Nikoskelainen J
Teräsjärvi MR
P304
P356
10.1080/003655400458749
P577
2000-01-01T00:00:00Z